A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness
NCT ID: NCT01959659
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1431 participants
OBSERVATIONAL
2013-05-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have a clinical diagnosis of schizophrenia as documented in their medical records
* Patients who, in the opinion of the investigator, have had on-going, persistent symptoms of schizophrenia for at least the last 3 months prior to enrolment
* Patients who, in the opinion of the investigator, have been prescribed adequate doses of antipsychotic treatment for at least the last 3 months
* Patient has adequate spoken local language
Exclusion Criteria
* Enrolment in an interventional study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Epping, New South Wales, Australia
Everton Park, Queensland, Australia
Brno, , Czechia
Brno, Jihormoravsky Kraj, , Czechia
Hradec Králové, , Czechia
Olomouc, , Czechia
Pilsen, , Czechia
Prague, , Czechia
Prague, , Czechia
Prague, , Czechia
Prague, , Czechia
Prague, , Czechia
Praha 8 - Bohnice, , Czechia
Přerov, , Czechia
Bohars, , France
Bron, , France
Brumath, , France
Colombes, , France
Digne-les-Bains, , France
Fitz-James, , France
Hénin-Beaumont, , France
Leyme, , France
Lille, , France
Montauban, , France
Montpellier, , France
Neuilly-sur-Marne, , France
Novillars, , France
Paris, , France
Poitiers, , France
Pontarlier, , France
Provins, , France
Reims, , France
Rennes, , France
Saint-Égrève, , France
Saint-Nazaire, , France
Sens, , France
Verdun, , France
Chieti, Abruzzo, Italy
L’Aquila, Abruzzo, Italy
Aosta, Aosta Valley, Italy
Foggia, Apulia, Italy
Roggiano Gravina, Calabria, Italy
Salerno, Campania, Italy
Solofra, Campania, Italy
Bologna, Emilia-Romagna, Italy
Modena, Emilia-Romagna, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Genoa, Liguria, Italy
Bergamo, Lombardy, Italy
Brescia, Lombardy, Italy
Legnago, Lombardy, Italy
Monza, Lombardy, Italy
Pieve di Coriano, Lombardy, Italy
Varese, Lombardy, Italy
Campobasso, Molise, Italy
Novara, Piedmont, Italy
Adrano, Sicily, Italy
Lido di Camaiore, Tuscany, Italy
Pisa, Tuscany, Italy
Siena, Tuscany, Italy
Kemerovo, , Russia
Lipetsk, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow Region, , Russia
Nizhny Novgorod, , Russia
Petrozavodsk, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Samara, , Russia
Talagi, , Russia
Almería, Almeria, Spain
Manacor, Balearic Islands, Spain
Barcelona, Barcelona, Spain
Barcelona, Barcelona, Spain
L'Hospitalet de Llobregat, Barcelona, Spain
Santander, Cantabria, Spain
Torrelavega, Cantabria, Spain
A Coruña, La Coruña, Spain
Alcalá de Henares, Madrid, Spain
Arganda, Madrid, Spain
Madrid, Madrid, Spain
Majadahonda, Madrid, Spain
Málaga, Malaga, Spain
Pamploma, Navarre, Spain
Mos, Pontevedra, Spain
Vigo, Pontevedra, Spain
Langreo, Principality of Asturias, Spain
Dos Hermanas, Sevilla, Spain
Reus, Tarragona, Spain
Toledo, Toledo, Spain
Valencia, Valencia, Spain
Valencia, Valencia, Spain
Vitoria-Gasteiz, Vizcaya, Spain
Zaragoza, Zaragoza, Spain
Ankara, , Turkey (Türkiye)
Diyarbakır, , Turkey (Türkiye)
Gaziantep, , Turkey (Türkiye)
Istanbul, , Turkey (Türkiye)
Istanbul, , Turkey (Türkiye)
Kocaeli, , Turkey (Türkiye)
Manisa, , Turkey (Türkiye)
Mersin, , Turkey (Türkiye)
Samsun, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MN28222
Identifier Type: -
Identifier Source: org_study_id